Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab vedotin vs chemotherapy in previously treated advanced urothelial cancer
NCT03474107Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of enfortumab vedotin in urothelial carcinoma (UC), sponsored by Astellas Pharma. Started Jun 2018; status: completed.
02
Drugs
enfortumab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03474107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474107.